India Gets Its First Dengue Vaccine as DCGI Approves QDENGA
In a major breakthrough for public health, India has approved its first dengue vaccine, QDENGA, developed by Japanese pharmaceutical company Takeda. The approval was granted by the Drugs Controller General of India (DCGI), making QDENGA the first vaccine authorized in the country to help prevent dengue infection. The vaccine is approved for individuals aged 4 to 60 years and targets all four dengue virus serotypes.
The approval comes at a crucial time, as dengue cases in India have increased significantly over the past two decades, making the disease a major public health concern.
What Is QDENGA?
QDENGA (also known as TAK-003) is a live attenuated tetravalent dengue vaccine developed by Takeda Pharmaceutical.
It is designed to provide protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). Unlike some earlier dengue vaccines, QDENGA can be administered regardless of whether a person has previously had dengue, eliminating the need for pre-vaccination blood testing.
Who Can Receive the Vaccine?
According to the DCGI approval, QDENGA is indicated for:
- Individuals 4 to 60 years of age
- People with or without a previous dengue infection
Doctors will still determine whether the vaccine is appropriate for each individual based on medical history and current health conditions.
How Is QDENGA Given?
QDENGA is administered as:
- Two doses
- 0.5 ml each
- Three months apart
Completing both doses is important to achieve the intended level of protection.
How Effective Is the Vaccine?
Clinical studies have shown encouraging results.
According to Takeda’s trial data, QDENGA demonstrated:
- 80.2% effectiveness against confirmed dengue infection.
- 90.4% effectiveness in preventing dengue-related hospitalizations.
While the vaccine significantly reduces the risk of severe disease, it does not provide 100% protection, so mosquito-bite prevention remains essential.
Why Is a Dengue Vaccine Important?
Dengue is a mosquito-borne viral disease spread by Aedes mosquitoes. India reports lakhs of dengue cases every year, especially during and after the monsoon season.
Symptoms may include:
- High fever
- Severe headache
- Muscle and joint pain
- Skin rash
- Nausea and vomiting
In severe cases, dengue can lead to internal bleeding, shock, organ failure, and death if not treated promptly. A vaccine can help reduce the burden of severe illness and hospitalizations.
When Will QDENGA Be Available in India?
Although the vaccine has now received regulatory approval, Takeda expects to launch QDENGA in India’s private healthcare market during the first half of 2027.
The company is also expanding manufacturing capacity, with Indian vaccine manufacturer Biological E expected to support production for global supply.
Will Vaccination Replace Mosquito Prevention?
No.
Health experts emphasize that vaccination should be combined with mosquito-control measures, including:
- Using mosquito repellents.
- Wearing full-sleeved clothing.
- Installing window screens.
- Removing stagnant water around homes.
- Seeking medical attention if dengue symptoms appear.
Even after vaccination, these precautions remain important because no vaccine offers complete protection.
Why Developing a Dengue Vaccine Is Challenging
Creating a dengue vaccine has been scientifically difficult because the disease is caused by four different virus serotypes.
Infection with one serotype does not provide full immunity against the others, and a second infection with a different serotype can sometimes lead to more severe disease. A successful vaccine therefore needs to provide balanced protection against all four serotypes.
A Major Milestone for India
The approval of QDENGA marks an important step in India’s fight against dengue. Along with improved surveillance, mosquito-control programs, and public awareness campaigns, vaccination could significantly reduce severe dengue cases and related hospitalizations in the coming years.
As the vaccine becomes available, it is expected to strengthen India’s public health response against one of the country’s most widespread mosquito-borne diseases.
Conclusion
India’s approval of QDENGA, the country’s first dengue vaccine, represents a significant advancement in dengue prevention. Approved for people aged 4 to 60 years, the two-dose vaccine offers strong protection against all four dengue virus serotypes and has demonstrated high effectiveness in reducing severe illness and hospitalization. While vaccination is a major milestone, experts stress that mosquito control and personal protective measures will continue to play a vital role in preventing dengue.
Frequently Asked Questions (FAQs)
1. What is QDENGA?
QDENGA is India’s first approved dengue vaccine, developed by Takeda, that protects against all four dengue virus serotypes.
2. Who can receive the dengue vaccine in India?
The vaccine is approved for individuals aged 4 to 60 years, regardless of previous dengue infection.
3. How many doses of QDENGA are required?
QDENGA is given in two doses, administered three months apart.
4. How effective is the vaccine?
Clinical trials showed 80.2% effectiveness against confirmed dengue and 90.4% effectiveness against dengue-related hospitalization.
5. When will QDENGA be available in India?
Takeda plans to launch the vaccine in India’s private healthcare market during the first half of 2027.
6. Will vaccinated people still need mosquito protection?
Yes. Vaccination reduces the risk of severe disease but does not eliminate the need for mosquito-bite prevention measures such as repellents, protective clothing, and eliminating stagnant water.